Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (INNMF)
OTHER OTC:INNMF
INNMF Stock Chart & Stats
$0.09
$0.02(38.01%)
At close: 4:00 PM EST
$0.09
$0.02(38.01%)
Day’s Range― - ―
52-Week Range$0.03 - $0.27
Previous CloseN/A
Volume1.10K
Average Volume (3M)12.53K
Market Cap
$43.51M
Enterprise Value$27.66M
Total Cash (Recent Filing)$29.16M
Total Debt (Recent Filing)$381.42K
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding513,071,660
10 Day Avg. Volume2,756
30 Day Avg. Volume12,526
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.02
Price to Sales (P/S)5.68
P/FCF Ratio-3.12
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue11.64
Enterprise Value/Gross Profit12.57
Enterprise Value/Ebitda-2.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently >90% gross margins indicate strong unit economics for the company’s products and services. That margin durability supports continued investment in R&D and absorbes development costs, improving the odds the firm can sustain operations and fund trials longer without immediate revenue conversion.
Conservative Balance SheetLow leverage and a healthy equity ratio provide financial flexibility and reduce insolvency risk during lengthy clinical development. This conservatism preserves options to raise capital on better terms, supports continued operations through trial cycles, and cushions against unexpected setbacks.
Focused R&D PipelineA clear strategic focus on FAK inhibition and a lead candidate (narmafotinib/AMP945) concentrates scientific expertise and resource allocation. This focus can accelerate development decisions, make partnering/licensing clearer, and enhance the company’s credibility with specialized investors and collaborators long-term.
Bears Say
Persistent Operating LossesOngoing negative net margins and losses are structural for a development biotech and will require recurring external funding. Persistent losses compress retained capital, increase dilution risk from equity raises, and limit the company’s ability to self-finance later-stage trials without strategic partnerships or new capital.
Negative Operating And Free Cash FlowNegative operating and free cash flows mean the company burns cash to fund R&D and operations. This creates dependency on external financing and can force timing trade-offs for clinical programs, delaying milestones or shrinking trial scope if capital is constrained, affecting long-term development timelines.
Single-asset Concentration RiskHeavy dependence on a single lead candidate and modality concentrates binary clinical and regulatory risk: trial failure or safety setbacks would materially damage prospects. Limited pipeline diversification increases the long-term probability that one adverse outcome could significantly impair growth and partnership options.
Amplia Therapeutics News
INNMF FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest stock price was $0.03 and its highest was $0.27 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is $43.51M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 87 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in INNMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
INNMF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $153.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-27.39%
Trailing 12-Months
Asset Growth
199.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Noxopharm Ltd.
―
Nanollose Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---